Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:1761-1774
Published online before print August 12, 2004, doi: 10.1161/01.ATV.0000142363.15113.88
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
24/10/1761    most recent
01.ATV.0000142363.15113.88v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Melo, L. G.
Right arrow Articles by Dzau, V. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Melo, L. G.
Right arrow Articles by Dzau, V. J.
Related Collections
Right arrow Gene regulation
Right arrow Gene therapy
Right arrow Oxidant stress
Right arrow Endothelium/vascular type/nitric oxide
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:1761.)
© 2004 American Heart Association, Inc.

Brief Reviews

Endothelium-Targeted Gene and Cell-Based Therapies for Cardiovascular Disease

Luis G. Melo; Massimiliano Gnecchi; Alok S. Pachori; Deling Kong; Kai Wang; Xiaoli Liu; Richard E. Pratt; Victor J. Dzau

From the Department of Physiology (L.G.M., K.W., X.L.), Queen’s University, Kingston, Ontario, Canada; and the Department of Medicine (L.G.M., M.G., A.S.P., D.K., R.E.P., V.J.D.), Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass.

Correspondence to Dr Luis G. Melo, Department of Physiology, Queen’s University, 18 Stuart Street, Kingston, Ontario, K7L 3N6, Canada. E-mail melol{at}post.queensu.ca

Most common cardiovascular diseases are accompanied by endothelial dysfunction. Because of its predominant role in the pathogenesis of cardiovascular disease, the vascular endothelium is an attractive therapeutic target. The identification of promoter sequences capable of rendering endothelial-specific transgene expression together with the recent development of vectors with enhanced tropism for endothelium may offer opportunities for the design of new strategies for modulation of endothelial function. Such strategies may be useful in the treatment of chronic diseases such as hypertension, atherosclerosis, and ischemic artery disease, as well as in acute myocardial infarction and during open heart surgery for prevention of ischemia and reperfusion (I/R)-induced injury. The recent identification of putative endothelial progenitor cells in peripheral blood may allow the design of autologous cell-based strategies for neovascularization of ischemic tissues and for the repair of injured blood vessels and bioengineering of vascular prosthesis. "Proof-of-concept" for some of these strategies has been established in animal models of cardiovascular disease. However the successful translation of these novel strategies into clinical application will require further developments in vector and delivery technologies. Further characterization of the processes involved in mobilization, migration, homing, and incorporation of endothelial progenitor cells into the target tissues is necessary, and the optimal conditions for therapeutic application of these cells need to be defined and standardized.

Endothelial dysfunction plays a pivotal role in cardiovascular disease. The recent isolation of endothelial progenitor cells together with the availability of promoter sequences and vectors capable of rendering endothelial-specific transgene expression may offer opportunities for the design of novel therapeutic strategies for improvement of endothelial function in cardiovascular disease.


Key Words: endothelial progenitor cells • endothelial-specific expression • gene therapy • targeting • viral vectors




This article has been cited by other articles:


Home page
 StrokeHome page
H. Froehlich, R. Gulati, B. Boilson, T. Witt, A. Harbuzariu, L. Kleppe, A. B. Dietz, A. Lerman, and R. D. Simari
Carotid Repair Using Autologous Adipose-Derived Endothelial Cells
Stroke, May 1, 2009; 40(5): 1886 - 1891.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
I. Hecht, J. Rong, A. L. F. Sampaio, C. Hermesh, C. Rutledge, R. Shemesh, A. Toporik, M. Beiman, L. Dassa, H. Niv, et al.
A Novel Peptide Agonist of Formyl-Peptide Receptor-Like 1 (ALX) Displays Anti-Inflammatory and Cardioprotective Effects
J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 426 - 434.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Deckers, B. Quesson, J. Arsaut, S. Eimer, F. Couillaud, and C. T. W. Moonen
Image-guided, noninvasive, spatiotemporal control of gene expression
PNAS, January 27, 2009; 106(4): 1175 - 1180.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A.-L. Levonen, E. Vahakangas, J. K. Koponen, and S. Yla-Herttuala
Antioxidant Gene Therapy for Cardiovascular Disease: Current Status and Future Perspectives
Circulation, April 22, 2008; 117(16): 2142 - 2150.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
R. Khurana, M. Simons, J. F. Martin, and I. C. Zachary
Role of Angiogenesis in Cardiovascular Disease: A Critical Appraisal
Circulation, September 20, 2005; 112(12): 1813 - 1824.
[Abstract] [Full Text] [PDF]


ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.